TXNDC12 and cancer: Considering c-Myc’s status as ‘difficult-to-drug’ or ‘undruggable’27, our findings highlight the targeting of TXNDC12 as a novel and effective approach to circumvent the challenges posed by c-Myc in cancer therapy, underscoring the importance of this strategy in advancing cancer treatment.